Acadian Asset Management
QNCX icon

Acadian Asset Management’s Quince Therapeutics QNCX Stock Holding History

Acadian Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,754
Closed -$176K – 2190
2026
Q1 		$176K Buy
8,754
+8,667
+9,962% +$1.74M ﹤0.01% 1624
2025
Q4 		$57K Buy
+87
New +$43.8K ﹤0.01% 1773
2023
Q2 		– Sell
-234
Closed -$73K – 1875
2023
Q1 		$73K Sell
234
-535
-70% -$105K ﹤0.01% 1454
2022
Q4 		$96K Hold
769
– – ﹤0.01% 1445
2022
Q3 		$203K Sell
769
-83
-10% -$31.6K ﹤0.01% 1208
2022
Q2 		$378K Buy
+852
New +$602K ﹤0.01% 1057

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management's QNCX Position: Q2 2026 in Review

Acadian Asset Management sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 8,754 shares — an estimated $176K sold.

Acadian Asset Management first reported a position in QNCX in Q2 2022 and held it in 6 quarters. The position peaked at $378K in Q2 2022. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Acadian Asset Management reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 8,754 Quince Therapeutics shares in Q2 2026, an estimated $176K.
  • Acadian Asset Management first reported a position in Quince Therapeutics in Q2 2022 and held it in 6 quarters.
  • Acadian Asset Management's Quince Therapeutics position peaked at $378K in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.